Recurrence of Clostridioides difficile infection and mortality in older inpatients.
Clostridioides difficile infection
Aged
Mortality
Recurrence
Journal
European geriatric medicine
ISSN: 1878-7649
Titre abrégé: Eur Geriatr Med
Pays: Switzerland
ID NLM: 101533694
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
20
10
2023
accepted:
10
01
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
The prevalence of Clostridioides difficile infection in older and frail population is extremely high and adverse outcomes, including future recurrences and premature mortality, are common. Nonetheless, the clinical risk profile for Clostridioides difficile recurrence in older people is still controversial. We aimed to investigate: 1) the association between Clostridioides difficile recurrence and 6-month mortality; 2) the risk factors for Clostridioides difficile recurrence after hospital discharge. This is a retrospective study on adults with a first episode of Clostridioides difficile infection admitted to all Internal Medicine and Geriatrics Units of the University Hospital of Ferrara (Italy) between January 2018 and December 2020. For each patient, sociodemographic, clinical and laboratory data were collected through hospital database system. The primary and secondary outcomes were mortality and recurrence within 6 months from the first infectious episode, respectively. The mean age of the 386 enrolled patients was 77.8 years; 61.7% were females. Twelve percent patients had Clostridioides difficile recurrence and 32.1% patients died during the 6-month follow-up. At Cox analysis, after adjustment for the potential confounders, participants with recurrence reported a twofold risk of death compared to those without recurrence (HR, 95% CI 2.45, 1.59-3.78). Compared to patients treated with metronidazole, those treated with vancomycin showed a lower risk of recurrence (log-rank p < 0.001). Clostridioides difficile recurrence is associated with a higher risk of mortality and it may itself be a marker of frailty and vulnerability. Vancomycin treatment during the infectious episode was associated with lower recurrence rate, as compared to metronidazole.
Identifiants
pubmed: 38448711
doi: 10.1007/s41999-024-00942-x
pii: 10.1007/s41999-024-00942-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to European Geriatric Medicine Society.
Références
McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE et al (2018) Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66:e1-48. https://doi.org/10.1093/cid/cix1085
doi: 10.1093/cid/cix1085
pubmed: 29462280
pmcid: 6018983
Khanna S, Pardi DS (2010) The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 4:409–416. https://doi.org/10.1586/egh.10.48
doi: 10.1586/egh.10.48
pubmed: 20678014
Guery B, Menichetti F, Anttila V-J, Adomakoh N, Aguado JM, Bisnauthsing K et al (2018) Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis 18:296–307. https://doi.org/10.1016/S1473-3099(17)30751-X
doi: 10.1016/S1473-3099(17)30751-X
pubmed: 29273269
Feuerstadt P, Nelson WW, Drozd EM, Dreyfus J, Dahdal DN, Wong AC et al (2022) Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults. J Am Med Dir Assoc 23:1721-1728.e19. https://doi.org/10.1016/j.jamda.2022.01.075
doi: 10.1016/j.jamda.2022.01.075
pubmed: 35288083
Archbald-Pannone L, Sevilleja JE, Guerrant R (2010) Diarrhea, clostridium difficile, and intestinal inflammation in residents of a long-term care facility. J Am Med Dir Assoc 11:263–267. https://doi.org/10.1016/j.jamda.2009.09.006
doi: 10.1016/j.jamda.2009.09.006
pubmed: 20439046
pmcid: 2864938
Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN (2006) Proton pump inhibitors and hospitalization for clostridium difficile-associated disease: a population-based study. Clin Infect Dis 43:1272–1276. https://doi.org/10.1086/508453
doi: 10.1086/508453
pubmed: 17051491
Gómez S, Chaves F, Orellana MA (2017) Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection. Anaerobe 48:147–151. https://doi.org/10.1016/j.anaerobe.2017.08.012
doi: 10.1016/j.anaerobe.2017.08.012
pubmed: 28830842
Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V et al (2009) Prospective derivation and validation of a clinical prediction rule for recurrent clostridium difficile infection. Gastroenterology 136:1206–1214. https://doi.org/10.1053/j.gastro.2008.12.038
doi: 10.1053/j.gastro.2008.12.038
pubmed: 19162027
van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B et al (2021) European society of clinical microbiology and infectious diseases: 2021 update on the treatment guidance document for clostridioides difficile infection in adults. Clin Microbiol Infect 27:S1-21. https://doi.org/10.1016/j.cmi.2021.09.038
doi: 10.1016/j.cmi.2021.09.038
pubmed: 34678515
Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER (2015) Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect 21:164–170. https://doi.org/10.1016/j.cmi.2014.08.017
doi: 10.1016/j.cmi.2014.08.017
pubmed: 25658560
Kelly CP (2012) Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol and Infect 18:21–27. https://doi.org/10.1111/1469-0691.12046
doi: 10.1111/1469-0691.12046
Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA et al (2012) Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 55:S93-103. https://doi.org/10.1093/cid/cis499
doi: 10.1093/cid/cis499
pubmed: 22752871
pmcid: 3388031
Al Momani LA, Abughanimeh O, Boonpherg B, Gabriel JG, Young M (2018) Fidaxomicin vs vancomycin for the treatment of a first episode of Clostridium Difficile infection: a meta-analysis and systematic review. Cureus. https://doi.org/10.7759/cureus.2778
doi: 10.7759/cureus.2778
pubmed: 30148007
pmcid: 6104896
Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN et al (2018) Bezlotoxumab for prevention of recurrent clostridium difficile infection in patients at increased risk for recurrence. Clin Infect Dis 67:649–656. https://doi.org/10.1093/cid/ciy171
doi: 10.1093/cid/ciy171
pubmed: 29538686
pmcid: 6093994
Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N et al (2017) Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 46:479–493. https://doi.org/10.1111/apt.14201
doi: 10.1111/apt.14201
pubmed: 28707337
Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S et al (2017) Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 17:990–1001. https://doi.org/10.1016/S1473-3099(17)30325-0
doi: 10.1016/S1473-3099(17)30325-0
pubmed: 28629876
Crobach MJT, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM et al (2016) European society of clinical microbiology and infectious diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 22:S63-81. https://doi.org/10.1016/j.cmi.2016.03.010
doi: 10.1016/j.cmi.2016.03.010
pubmed: 27460910
Guinta MM, Bunnell K, Harrington A, Bleasdale S, Danziger L, Wenzler E (2017) Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile. Ann Clin Microbiol Antimicrob 16:77. https://doi.org/10.1186/s12941-017-0252-7
doi: 10.1186/s12941-017-0252-7
pubmed: 29202797
pmcid: 5713042
Deyo R, Cherkin D (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619. https://doi.org/10.1016/0895-4356(92)90133-8
doi: 10.1016/0895-4356(92)90133-8
pubmed: 1607900
R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing 2008.
Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N et al (2011) Host and pathogen factors for Clostridium difficile Infection and colonization. NEJM 365:1693–1703. https://doi.org/10.1056/NEJMoa1012413
doi: 10.1056/NEJMoa1012413
pubmed: 22047560
Karanika S, Grigoras C, Flokas ME, Alevizakos M, Kinamon T, Kojic EM et al (2017) The attributable burden of clostridium difficile infection to long-term care facilities stay: a clinical study. J Am Geriatr Soc 65:1733–1740. https://doi.org/10.1111/jgs.14863
doi: 10.1111/jgs.14863
pubmed: 28306141
Ticinesi A, Nouvenne A, Folesani G, Prati B, Morelli I, Guida L et al (2015) Multimorbidity in elderly hospitalised patients and risk of Clostridium difficile infection: a retrospective study with the Cumulative Illness Rating Scale (CIRS). BMJ Open 5:e009316. https://doi.org/10.1136/bmjopen-2015-009316
doi: 10.1136/bmjopen-2015-009316
pubmed: 26503394
pmcid: 4636642
Ticinesi A, Milani C, Lauretani F, Nouvenne A, Mancabelli L, Lugli GA et al (2017) Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci Rep 7:11102. https://doi.org/10.1038/s41598-017-10734-y
doi: 10.1038/s41598-017-10734-y
pubmed: 28894183
pmcid: 5593887
Rockwood K (2005) A global clinical measure of fitness and frailty in elderly people. Can Med Assoc J 173:489–495. https://doi.org/10.1503/cmaj.050051
doi: 10.1503/cmaj.050051
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M157. https://doi.org/10.1093/gerona/56.3.M146
doi: 10.1093/gerona/56.3.M146
pubmed: 11253156
Olsen MA, Stwalley D, Demont C, Dubberke ER (2018) Increasing age has limited impact on risk of Clostridium difficile infection in an elderly population. Open Forum Infect Dis. https://doi.org/10.1093/ofid/ofy160
doi: 10.1093/ofid/ofy160
pubmed: 30619910
pmcid: 6306568
Rubak T, Baunwall SMD, Gregersen M, Hansen TK, Rosenbæk JB, Erikstrup LT et al (2023) Frailty level at discharge predicts mortality in older patients with Clostridioides difficile more accurately than age or disease severity. Eur Geriatr Med 14:583–593. https://doi.org/10.1007/s41999-023-00772-3
doi: 10.1007/s41999-023-00772-3
pubmed: 37046032
pmcid: 10097521
Rao K, Micic D, Chenoweth E, Deng L, Galecki AT, Ring C et al (2013) Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc 61:1738–1742. https://doi.org/10.1111/jgs.12442
doi: 10.1111/jgs.12442
pubmed: 24083842
pmcid: 3801297
Govoni B, Zurlo A, De Giorgio R, Cultrera R, Volpato S (2020) Clostridium difficile infection in a geriatric care unit: clinical characteristics and prognosis. JGG 69:1–5. https://doi.org/10.36150/2499-6564-419
doi: 10.36150/2499-6564-419
Song JH, Kim YS (2019) Recurrent Clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver 13:16–24. https://doi.org/10.5009/gnl18071
doi: 10.5009/gnl18071
pubmed: 30400734
Tart SB (2013) The role of vancomycin and metronidazole for the treatment of Clostridium difficile– associated diarrhea. J Pharm Pract 26:488–490. https://doi.org/10.1177/0897190013499525
doi: 10.1177/0897190013499525
pubmed: 23940121
Al-Jashaami LS, DuPont HL (2016) Management of Clostridium difficile infection. Gastroenterol Hepatol (N Y) 12:609–616
pubmed: 27917075
Chang LL, Allegretti J, Skinner AM, Dubberke ER (2023) Oral vancomycin as secondary prophylaxis for prevention of recurrent Clostridioides difficile infection. NEJM 388:654–656. https://doi.org/10.1056/NEJMclde2204692
doi: 10.1056/NEJMclde2204692
pubmed: 36791167
Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP et al (2021) Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 73:755–757. https://doi.org/10.1093/cid/ciab718
doi: 10.1093/cid/ciab718
pubmed: 34492699